| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33246 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF3018-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB3018-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF3018 | |||
| Carrier Free | AF3018-SP | |||
![Western Blot: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - Analysis in cell lysates from human brain using a dilution of 2 ug/ml.](http://images.novusbio.com/fullsize/PGLYRP4-PGRP-I-beta-Antibody-186C426-Western-Blot-NB100-56721-img0005.jpg "Western Blot: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - Analysis in cell lysates from human brain using a dilution of 2 ug/ml.")
![Immunocytochemistry/Immunofluorescence: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - A. HCECs were exposed to HKCA (106 cells/ml) with prior incubation in the absence or presence of isotype IgG (10ug/ml), dectin-1 neutralizing Ab (10ug/ml), BAY11-7082 (10uM) or NF-kB activation inhibitor quinazoline (NF-kB-I, 10uM) for 1 h. HCECs were treated with 106 cells/ml HKCA for 48 hours in 8-chamber slides and examined by immunofluorescent staining for PGLYRPs 3 (NB100-56729) and 4. C. The percentages of positive cells of PGLYRPs 3 and 4 staining in HCECs in A was quantified. Results shown are the mean +/- SD of four independent experiments; *** p<0.001, as compared with normal control; ^^ p<0.005, ^^^ p<0.001, as compared with HCECs exposed to HKCA. Magnification: 400x (bar = 25um). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0128039) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PGLYRP4-PGRP-I-beta-Antibody-186C426-Immunocytochemistry-Immunofluorescence-NB100-56721-img0006.jpg)
![Immunohistochemistry: PGLYRP4/PGRP-I beta Antibody (186C426) [NB100-56721] - NF-kappa B p65 activation was induced by HKCA & inhibited by dectin-1 neutralizing antibody & NF-kappa B activation inhibitor quinazoline (NF-kappa B-I) in HCECs.A. HCECs were exposed to HKCA (106 cells/ml) with prior incubation in the absence or presence of isotype IgG (10μg/ml), dectin-1 neutralizing Ab (10μg/ml), BAY11-7082 (10μM) or NF-kappa B activation inhibitor quinazoline (NF-kappa B-I, 10μM) for 1 h. HCECs were treated with 106 cells/ml HKCA for 48 hours in 8-chamber slides & examined by immunofluorescent staining for PGLYRPs 2–4. B. HCECs were treated for 4 hours in 8-chamber slides & were fixed in acetone for immunofluroscent staining total p65 (nuclear translocation) (green). C. The percentages of positive cells of PGLYRPs 2–4 staining in HCECs in A was quantified. D. The percentages of NF-ĸB p65 nuclear staining positive cells in B was quantified. Images are representatives from three independent experiments. Results shown are the mean ± SD of four independent experiments; *** p<0.001, as compared with normal control; ^^ p<0.005, ^^^ p<0.001, as compared with HCECs exposed to HKCA. Magnification: 400Х (bar = 25μm). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26039076), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56721_mouse-monoclonal-pglyrp4-pgrp-i-beta-antibody-186c426-310202415541937.jpg)
![Western Blot: PGLYRP4/PGRP-I beta Antibody [NBP3-09527] - Western blot analysis of PGLYRP4/PGRP-I beta in 293T Whole Cell lysates. Antibody dilution at 1.0ug/ml](http://images.novusbio.com/fullsize/PGLYRP4-PGRP-I-beta-Antibody-Western-Blot-NBP3-09527-img0001.jpg "Western Blot: PGLYRP4/PGRP-I beta Antibody [NBP3-09527] - Western blot analysis of PGLYRP4/PGRP-I beta in 293T Whole Cell lysates. Antibody dilution at 1.0ug/ml")